Skip to content

Converge Bio

AI antibody design for biotech and pharma teams

Raised to date

$25M

of $25M offered across 1 Form D filing

Investors
19
Last filed
Apr 28, 2026

About

Converge Bio builds generative AI systems for drug discovery, trained on DNA, RNA and protein sequences. Its ConvergeAB platform generates, predicts and optimizes antibody candidates, and the company also supports target discovery, protein manufacturing optimization and biomarker discovery for pharma and biotech customers. It raised a $25M Series A led by Bessemer Venture Partners in January 2026.

Proprietary models trained on over 1 trillion natural protein tokens, paired with wet-lab validation through partner CROs in a closed loop.

Funding

  • EquityFiled Apr 28, 2026Form D
    $25M/ $25M

Product

ConvergeAB

AI drug discovery platform

An AI antibody design platform that generates, scores and optimizes antibody sequences for affinity, developability, expression, humanization and structural fit.

  • Affinity maturation
  • Developability and expression optimization
  • Humanization and cross-reactivity tuning

Built for

Biotech and pharmaceutical drug discovery teams

People on file